Topic: Trading Tips

Suspension

None

Resuming

300205 ST Tianyu

[Hot spot]

huada zhizao : the company's business links do not involve data collection behavior

huada zhizao (688114) announced that on January 26, the company learned that huada zhizao was mentioned in a recent draft BIOSECURE Act proposed by the United States. Since its inception, the company has been adhering to the concept of "innovation and intelligence to lead life science and technology", is committed to becoming the "life science and technology core tool creator", through the deepening of platform application to enable customers to achieve more "read, write, save" innovation breakthrough and application scenario expansion. In the process of development, the company strictly abides by the laws and regulations of the operating market, and pays great attention to data security and privacy protection. As an upstream equipment provider in the gene sequencing industry, the company's business processes do not involve data collection, and the data generated by customers based on the company's sequencing platform are collected, stored, processed and controlled by the customers themselves.

Guosheng Technology : Chairman Wu Jun has been detained, and the matter involved has nothing to do with the company

Guosheng Technology (603778) announced that Wu Jun, the actual controller and chairman of the company, was detained on November 2, 2023 to cooperate with the Huai'an Supervisory Commission to assist in the investigation, but the matter involved has nothing to do with the company. As of the disclosure date of this announcement, the company has not received the relevant written notice of the above-mentioned lien, nor has it received any investigation or cooperation investigation documents from the competent authority. Although Wu Jun was detained, he was still able to perform his duties normally. The company has a sound governance structure and business control process, production and operation are carried out normally, and employees are paid in accordance with the relevant regulations of the company.

yaokang biology : all the technology and samples of the company are not within the scope of the draft biosafety bill

yaokang biology (688046) announced that recently, the company paid attention to the relevant statements concerning restricting the use of human genes and other genetic materials by Chinese biotechnology companies in a draft biosafety bill submitted to the U.S. House of Representatives on January 25, 2024. The company's model animal mice are produced using human genome sequences published by the scientific research community with no species differences, and do not involve any human source gene sequence analysis business. All technologies and samples are publicly available resources or commercially purchased resources in the research community and are not within the scope of the draft Biosafety Act. At the same time, we note that the draft has not yet entered into force, the relevant content still needs further consideration, there is a possibility of change. The company will also closely monitor the progress of the draft legislative process.

Mindray Medical : Proposed Acquisition Huitai Medical Control

Mindray Medical (300760) announced that the company plans to acquire 21.12 shares of Huitai Medical by agreement through its wholly-owned subsidiary Shenmai Control, with a total transfer amount of about 6.652 billion yuan. At the same time, Shenmai intends to transfer all 0.12 of the general partnership interests held by Chenyi Hongqi in Zhuhai Tongsheng, which currently holds 3.49 of the shares of Huitai Medical. After the completion of this transaction, Shenzhen Mai Control and its concerted action person Zhuhai Tongsheng hold a total of 24.61 shares of Huitai Medical, Huitai Medical controlling shareholder will be changed to Shenzhen Mai Control, the actual controller will be changed to Li Xiting and Xu Hang.

Nanjing-Shanghai Expressway : plans to acquire 65% equity of Suzhou-Wuxi-Chang Southern Expressway Company for about 5.2 billion yuan

Nanjing-Shanghai Expressway (600377) announced that in order to further expand the company's asset scale in the southern Jiangsu expressway network, the company plans to acquire 65% equity of Jiangsu Suzhou-Wuxi-Changzhou Southern Expressway Co., Ltd. (hereinafter referred to as "Suzhou-Wuxi-Changzhou Southern Expressway Company") for about 5.2 billion yuan. In addition, the Company also entered into a letter of intent with Wuxi Communications to initiate discussions on the acquisition of its 22.8 percent stake in Suxi-Chang Southern Expressway Company. Once the Company and Wuxi Transportation formally sign the Equity Transfer Agreement and complete the acquisition, the Company will own and control 87.8 of the absolute controlling equity interest in Suxi Chang Southern Expressway Company. In addition, the Company is actively seeking to acquire a 12.2 percent stake in Suxi-Changyi Southern Expressway Company, which is held by Changzhou High Investment.

[Performance]

shenma power: net profit in 2023 increased by 206.05-228.44% year on year

Shenma Electric Power (603530) released its annual results forecast, 2023 is expected to achieve a net profit of about 0.15 billion -0.161 billion yuan, up 206.05-228.44 year-on-year. During the reporting period, the company's annual operating income increased by about 30% over the same period last year. With the company's substation composite external insulation products continue to promote the overall overseas revenue to maintain a steady growth rate, at the same time, the transmission and distribution line composite external insulation products overseas revenue reporting period to achieve leapfrog growth, up more than 200, and medium-and long-term growth trend is good, will continue to provide incremental contribution to the company's performance.

sen Kirin: net profit in 2023 increased by 62.33-77.31% year on year

Sen Kirin (002984) released its earnings forecast, expecting a net profit of 1.3 billion -1.42 billion yuan in 2023, up 62.33-77.31 percent year-on-year. In 2023, the overall operating situation of China's tire industry, represented by Sen Kirin, recovered in an all-round way. In overseas markets, the company's high-quality and high-performance products have a cost-effective competitive advantage in the European and American tire markets, and the demand for orders continues to be in short supply; in the domestic market with high growth potential, it also shows a recovery trend. At the same time, in 2023, with the large-scale production of the company's Thailand Phase II project, Sen Kirin continued to maintain a steady growth trend.

great wall securities: net profit increased 55%-65% year-on-year in 2023

great wall securities (002939) issued a performance forecast, with a net profit of 1.393 billion -1.483 billion yuan expected to return to its parent in 2023, up 55%-65% year-on-year. In 2023, the company to innovation-driven performance growth, further enhance asset allocation capabilities, accelerate the transformation to a stable investment structure system, self-investment and other business operating performance rebounded significantly year-on-year.

first tour hotel: 2023 net profit pre-profit 0.77 billion yuan -0.83 billion yuan, a year-on-year turnaround

BTG Hotel (600258) issued an annual performance pre-profit announcement, and it is expected that the net profit attributable to shareholders of listed companies in 2023 will be 0.77 billion yuan to 0.83 billion yuan, a year-on-year turnaround. In 2023, along with the macroeconomic stability, business travel demand gradually recovered. In the first half of the year, the company seized the opportunity of rapid recovery of the hotel market and achieved a substantial year-on-year turnaround. In the third quarter, domestic demand for leisure tourism was high, and the company seized the opportunity of the summer sales season to take multiple measures to improve hotel profitability. Entering the fourth quarter of the traditional off-season, the company continued to improve quality and efficiency to promote operations, hotel RevPAR to achieve a steady recovery.

US year health: 2023 net profit pre-profit of 0.46 billion yuan -0.57 billion yuan, year-on-year loss

us year health (002044) issued a performance forecast, expected to return to the mother net profit of 0.46 billion yuan -0.57 billion yuan in 2023, a year-on-year turnaround. In 2023, the health examination industry recovered strongly, and the company's operation entered a benign development channel driven by demand and rising volume and price, promoting the company's operating performance to continue to grow and the high-quality development of enterprises.

Caibai shares: net profit in 2023 increased by 45.61-59.74% year on year

Caibai shares (605599) issued an annual performance pre-increase announcement. It is estimated that the net profit attributable to the owner of the parent company in 2023 will be 0.67 billion yuan to 0.735 billion yuan, a year-on-year increase of 45.61-59.74. In 2023, China's economy rebounded to the good, with a series of steady growth, consumer measures to promote consumption on the ground, the business environment continued to optimize, the consumer market rose to pick up, superimposed on the upward trend of gold price shocks, consumers' willingness to buy gold jewelry products increased.

hang seng electronics: net profit up about 23.27% year-on-year in 2023

Hang Seng Electronics (600570) released its annual performance forecast, and it is expected to achieve a net profit of about 1.345 billion yuan attributable to shareholders of listed companies in 2023, a year-on-year increase of about 23.27. In 2023, thanks to the impact of the digital transformation and upgrading of the financial industry, financial institutions continue to increase their investment in science and technology, the company continues to maintain its leading market position, and its operating income continues to grow.

kanglong into a: 2023 net profit increased 14%-19% year-on-year

Kanglong Huacheng (300759) issued a performance forecast, expected 2023 net profit of 1.567 billion yuan -1.636 billion yuan, up 14%-19% year-on-year. During the reporting period, the revenue of each company's business segment increased steadily, and the overall profit of the main business increased; macromolecule and cell and gene therapy services and some overseas operations were still in the early stage of investment, which reduced the growth rate of profits to a certain extent; mainly Affected by the price fluctuations of experimental monkeys, the income from changes in the fair value of biological assets during the reporting period decreased significantly compared with the same period last year, which reduced the growth rate of profits to a certain extent.

special information (rights protection):2023 net profit pre-loss of 0.3 billion yuan -0.22 billion yuan, year-on-year loss

special information (000070) issued a performance forecast, is expected to return to the mother net profit loss of 0.3 billion yuan -0.22 billion yuan in 2023, year-on-year loss. During the reporting period, the market expansion of individual mergers and acquisitions subsidiaries was less than expected, and it is expected that impairment provisions will be made for the goodwill and related asset groups involved. Several of the Company's major projects were refixed at the end of 2022, resulting in an increase in depreciation, amortization and other expenses in 2023.

Sichuan dragon python: net profit in 2023 decreased by 59.59-68.99% year on year

Sichuan Long Python (002312) issued a performance forecast, expected 2023 net profit of 0.33 billion yuan -0.43 billion yuan, down 59.59-68.99 percent year-on-year. During the reporting period, the business cycle of the company's industry declined, and the price of the company's products fell accordingly. In addition, the prices of main raw materials remained high. Multiple factors led to the net profit attributable to shareholders of listed companies and the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses decreased significantly compared with the same period of last year.

[increase or decrease]

Guobo Electronics: Shareholders voluntarily promise not to reduce their shares in the company

Guobo Electronics (688375) announced that based on confidence in the company's future development prospects and recognition of long-term investment value, Tianjin Fenghe Technology Partnership (Limited Partnership), a shareholder holding 7.45 of the company's shares, voluntarily promised to do so in the next 12 months (not to reduce its holdings of the company's shares in any way.

shengmei Shanghai: directors and some senior executives of the company plan to increase their shares in the company from 9 million yuan to 12 million yuan

shengmei Shanghai (688082) announced that the company's director and general manager Wang Jian, deputy general manager Chen fu (golden Kirin analyst) (golden Kirin analyst) ping, and board secretary Luo mingzhu intends to increase the company's shares by a total amount of not less than 9 million yuan and not more12 million yuan. This increase in the plan does not set a price range for the increase in shares.

Sign a large order

Tianyang Technology: Signed Cooperation Agreement with Hunan University on Financial Supercomputing Joint Innovation Center

Tianyang Science and Technology (300872) announced that the company and Hunan University adhere to the principle of "complementary advantages, mutual benefit and reciprocity", and intend to give full play to their respective advantages and jointly build a financial supercomputing research and development center based on the supercomputing platform of the National Supercomputing Changsha Center. The two parties signed the cooperation agreement, which will take effect from the date of signing and is valid for five years. The cooperation agreement stipulates that in the next five years from the date of signing the agreement, the company expects a total investment of not less than 0.2 billion yuan to Hunan University (National Supercomputing Changsha Center) for the construction of "Tianyang Science and Technology-Hunan University Financial Supercomputing Joint Innovation Center". The specific investment arrangement shall be determined according to the promotion and landing of the cooperation project.

Haochen Software: Subsidiary Signed Suzhou Industrial Software Application Innovation Center Cooperation Landing Agreement

Haochen Software (688657) announced that Suzhou Industrial Software Application Innovation Center Co., Ltd., a holding subsidiary, signed the "Suzhou Industrial Software Application Innovation Center" with Suzhou Bureau of Industry and Information Technology, Wuzhong District People's Government, and Huawei Cloud Computing Technology Co., Ltd. "Landing Agreement", all parties are based on the principle of "complementary advantages and win-win cooperation, we will cooperate in the joint construction of Suzhou Industrial Software Application Innovation Center and accelerate the promotion of industrial software technology innovation and application promotion.

[Repo]

xingrui technology: to repurchase shares from 30 million yuan to 60 million yuan

Xingrui Technology (002937) announced that the company intends to use its own funds to buy back the company's shares in a centralized bidding transaction for equity incentives or employee stock ownership plans. The total amount of funds to be used for repurchase shall not be less than 30 million yuan and shall not exceed 60 million yuan, and the price of repurchased shares shall not exceed 30 yuan/share.

[Other]

gengxing shares (rights protection): 34.71 of the company's shares held by the controlling shareholder zhonggeng group will be auctioned by judicial disposal

Gengxing shares (600753) announced that the 79.9296 million shares of the company held by the controlling shareholder Zhonggeng Real Estate Group Co., Ltd. ("Zhonggeng Group") are to be judicially disposed of and auctioned, accounting for 97.56 of the company's shares. 34.71 of the company's total share capital. If this judicial auction is successful, it may lead to the risk that the actual controller and controlling shareholder of the company will change or the company will become a non-actual controller.

Northeast Pharmaceuticals: drug substance levocarnitine received CEP certificate issued by the European Drug Quality Agency

Northeast Pharmaceuticals (000597) announced that the company's raw material drug levocarnitine recently received the European Pharmacopoeia Applicability Certificate (CEP Certificate) issued by the European Drug Quality Administration, which is used to prevent and treat the lack of levocarnitine.